The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis B Virus Destroyed by Inovio's Vaccine

Back to News Homepage

Next

Trial Enrollment Begins for Abbott's Hep C Trio

BIT225 in Phase II Trial for HIV and Hep C Co-Infection

November 15, 2012

Print this page

In combination with interferon and ribavirin, Biotron’s experimental drug, BIT225, is now being tested in a Phase II trial for those co-infected with Hepatitis C and HIV.

Biotron begins key human trial of HIV/HCV drug

Friday, November 09, 2012 by Angela Kean

Biotron (ASX: BIT) has begun a landmark phase two human trial of its lead antiviral drug candidate, BIT225, in patients that are co-infected with both HIV and the Hepatitis C virus (HCV).

Twelve HIV/HCV-positive patients will receive 28 days treatment with BIT225 – 300 milligrams, twice daily – in combination with the standard approved treatment, interferon and ribavirin, for HCV.

The trial, which is being conducted at the Siriraj Hospital in Bangkok, is currently recruiting patients and is expected to be completed in the first half of 2013.

Continue reading this entire article:
http://www.proactiveinvestors.com.au/companies/news/35666/biotron-begins-key-human-trial-of-hivhcv-drug–35666.html

No Comments - be the first!
Share
Share

Previous

Hepatitis B Virus Destroyed by Inovio's Vaccine

Back to News Homepage

Next

Trial Enrollment Begins for Abbott's Hep C Trio

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.